Quantification of Visual Field Loss in Age-Related Macular Degeneration

Jennifer H. Acton1,2*, Jonathan M. Gibson2,3, Robert P. Cubbidge2

1 Department of Ophthalmology, New York University, New York, New York, United States of America, 2 Ophthalmic Research Group, Optometry & Vision Sciences, School of Life and Health Sciences, Aston University, Birmingham, United Kingdom, 3 Birmingham and Midland Eye Centre, Birmingham, United Kingdom

Abstract

Background: An evaluation of standard automated perimetry (SAP) and short wavelength automated perimetry (SWAP) for the central 10–2 visual field test procedure in patients with age-related macular degeneration (AMD) is presented in order to determine methods of quantifying the central sensitivity loss in patients at various stages of AMD.

Methods: 10–2 SAP and SWAP Humphrey visual fields and stereoscopic fundus photographs were collected in 27 eyes of 27 patients with AMD and 22 eyes of 22 normal subjects.

Results: Mean Deviation and Pattern Standard Deviation (PSD) varied significantly with stage of disease in SAP (both p<0.001) and SWAP (both p<0.001), but post hoc analysis revealed overlap of functional values among stages. In SWAP, indices of focal loss were more sensitive to detecting differences in AMD from normal. SAP defects were greater in depth and area than those in SAP. Central sensitivity (within 1°) changed by −3.9 and −4.9 dB per stage in SAP and SWAP, respectively. Based on defect maps, an AMD Severity Index was derived.

Conclusions: Global indices of focal loss were more sensitive to detecting early stage AMD from normal. The SWAP sensitivity decline with advancing stage of AMD was greater than in SAP. A new AMD Severity Index quantifies visual field defects on a continuous scale. Although not all patients are suitable for SWAP examinations, it is of value as a tool in research studies of visual loss in AMD.

Introduction

Age-related macular degeneration (AMD) is the third leading cause of blindness in the world and accounts for blindness in 8.7% of the global population [1]. Due to the increasing elderly population, it is expected that 17.8 million individuals in the US will be affected by 2050 [2]. The functional loss of central vision due to age-related macular degeneration (AMD) is well documented. However of the studies investigating visual field loss in AMD, some reported reduced threshold values [3,4,5,6,7] whilst others did not [8,9,10,11] and these discrepant findings may reflect differing methods of fundus grading and analyses. In addition no attempt has previously been made to quantify the visual field loss at each stage of severity of AMD. Such knowledge improves our understanding of the natural disease process in terms of visual function and the development of retinal changes. The early identification of patients who would benefit from treatment may help improve visual prognosis.

Past studies evaluating central visual field loss in AMD using non-standard procedures have shown foveal flicker sensitivity to be affected in early AMD [12] and greater flicker perimetry deficits [13]. A number of other techniques have also found functional deficits in AMD, including scotopic sensitivity testing [14,15,16], multifocal electroretinogram [17,18] and preferential hyperacuity perimetry [19]. However these techniques are not readily available for clinical use.

Evidence of short-wavelength sensitivity (SWS) pathway vulnerability in retinal disease suggests the usefulness of short-wavelength automated perimetry (SWAP) in monitoring AMD progression. This is supported by findings of SWS pathway deficits in AMD [20,21,22], SWAP sensitivity loss in eyes with soft drusen [6] and in eyes with diabetic retinopathy [23], and the earlier detection of glaucomatous visual field progression by SWAP [24,25]. Although the use of 30–2 and 24–2 SWAP fields is not clinically widespread due to their greater variability compared to SAP fields [26], the flatter profile of the hill of vision for the 10–2 field allows for more accurate statistical interpretation and greater capability in the detection of focal loss [27].

The aims of the study were to quantify the central visual field loss in a cross-section of AMD patients in standard automated perimetry (SAP) and SWAP. Secondary aims were to evaluate the location of visual field loss in AMD and the appropriate statistical measures that describe visual field loss.
Methods

Subjects

Subjects were recruited from Birmingham and Midland Eye Centre and the Aston University Eye Clinic. Based on 10° SWAP variability values from the normative database and from a previous study in patients [28], a sample of 7 at each stage would give 80% confidence of detecting a difference of 1.34 dB in mean sensitivity. The sample consisted of 27 patients (mean age 68.8 ± 7.8 years, range 46–84 years, 8 males, 19 females) with a diagnosis of AMD and 22 age-matched healthy controls (mean age 67.2 ± 7.5 years, range 49–78 years, 13 males, 9 females). Subjects had SAP experience but were naïve to SWAP. All study eyes met the inclusion criteria of refraction less than ±6.00 DS and ±2.00 DC, clear ocular media (Lens Opacity Classification System III [29], NC3, NO3, C1 and P1), no pseudophakia,

![Figure 1. Stages of AMD. Example fundus images of stages of AMD. Top left: Stage 0, top right: Stage 1, middle left: Stage 2, middle right: Stage 3, bottom left: Stage 4 atrophic AMD, bottom right: Stage 4 neovascular AMD. doi:10.1371/journal.pone.0039944.g001](image)

| Stage | Definition |
|-------|------------|
| Stage 0 | No signs of AMD, or presence of hard drusen (<63µm) only |
| Stage 1 | Soft distinct drusen (≥63µm) only, or pigmented abnormalities only |
| Stage 2 | Soft indistinct drusen (≥125µm) only, or soft distinct drusen (≥63µm) with pigmented abnormalities |
| Stage 3 | Soft indistinct (≥125µm) with pigmented abnormalities |
| Stage 4 | Atrophic or neovascular AMD |

Stages of disease were derived based a longitudinal 6.5 year epidemiologic study of progression rates of AMD [31]. See example images in Figure 1. doi:10.1371/journal.pone.0039944.t001
tonometry <21 mmHg (Pulsair, Keeler, Windsor, UK), normal optic nerve head appearance (assessed by ophthalmologist, JMG), no family history of glaucoma, no history of ocular disease other than untreated AMD, no ocular trauma, no systemic disease, no systemic medication known to influence the visual field, pupil diameters >3 mm and no congenital colour vision defect. Corrected visual acuity was at least 0.1 logMAR in each eye, in the normal group and ranged between 0–1 logMAR in the patient group. Four patients (of 31 who initially attended) were excluded from the study for non-foveal fixation, as assessed using the ophthalmoscope cross-hair fixation target or due to inability to complete a visual field test.

Written informed consent was obtained from each subject and the study had approval from the Aston University Human Sciences Ethical Committee and the NHS West Midlands Research Ethics Committee. The study followed the Tenets of the Declaration of Helsinki.

AMD Grading

Stereoscopic 30° fundus images were acquired (EOS 10D, 6.3 megapixels, Canon, Tokyo, Japan) and stored as high quality JPEG files (3072×2048) and viewed on a 20.1” 4is:3 monitor (1200×1600 pixel resolution), using a prismatic stereoviewer. Image grading [30] and stage of disease [31] (Table 1; Figure 1) was determined in a random order. Subjects who had any gradable features [30] were defined as belonging to the AMD patient group. All grading was determined by independent, masked graders (JMG & JHA), using custom written software (written in Liberty BASIC, Shoptalk Systems, Framingham, MA, USA), which mapped the circular grading grid to the fundus image and incorporated a measurement tool.

Perimetry

All subjects underwent visual field testing on the dominant eye, as determined by the hole-in-the-card test [32]. Each subject underwent SAP and SWAP 10–2 visual field examinations with the Humphrey Field Analyser 750 (Carl Zeiss Meditec, Dublin, CA, USA) on two occasions. For SAP, the stimulus size was 0.43° (Goldmann III) and the background luminance was 10 cd/m². For SWAP, blue (440 nm) 1.72° (Goldmann V) stimuli were presented on a yellow (>530 nm) 100 cd/m² background. SITA Standard and FASTPAC algorithms were employed for the SAP and SWAP fields, respectively, in order to mimic clinical practice as closely as possible. FASTPAC is the recommended strategy in SWAP [26] and SITA SWAP is not available for the 10–2 field. Visits were separated by 11 days, and the results from the first visit were discarded to account for the learning effect.

Before each examination, patients underwent three minutes of background adaptation. Fixation losses, false negative and false positive responses were less than 33%. Regular rest periods were given during and between examinations. The decision to include SAP (SITA standard) fields with false positives >15% and <33% was based on careful assessment of the video monitor gaze tracking function and the other parameters of fixation monitoring.

Analysis

Visual field change with stage of AMD was determined using the mean deviation (MD), pattern standard deviation (PSD), number of pattern deviation (PD) defects and local spatial variability (LSV). The LSV is a global index calculated as the root mean square of pointwise sensitivity differences between the raw and median filtered visual field [33]. All PD defects <3% were considered significant. The SAP MD and PSD were weighted indices from the HFA printout. Unweighted SWAP indices were calculated from a normal database collected previously. It consisted of 65 normal subjects (age 22–79) who performed 10–2 SWAP visual fields (FASTPAC). The normative data was analysed using univariate linear regression to give the age-corrected normal values at each stimulus location and the confidence intervals were calculated to derive probability defects.

Figure 2. Boxplots representing the change in the visual field with stage of severity of disease. The change in MD (dB), PSD (dB), LSV and number of PD defects as a function of stage of severity of disease, for standard automated perimetry (SAP) and short-wavelength automated perimetry (SWAP) is shown. Boxplot limits represent the 15th, 25th, 50th, 75th and 85th percentiles.

doi:10.1371/journal.pone.0039944.g002
Table 2. Summary table of global indices as a function of stage of severity of AMD.

|               | MS    | MD    | PSD   | LSV   | AMD Severity Index | No. PD defects |
|---------------|-------|-------|-------|-------|--------------------|----------------|
| Normals       | Mean  | 32.59 | 0.58  | 1.21  | 1.26               | 0.04           | 5.09           |
|               | SD    | 1.13  | 0.98  | 0.24  | 0.97               | 0.04           | 4.95           |
| Stage 0–1     | Mean  | 32.18 | 0.05  | 1.23  | 1.28               | 0.04           | 5.54           |
|               | SD    | 1.25  | 1.25  | 0.22  | 0.91               | 0.04           | 5.32           |
| Stage 2–3     | Mean  | 31.41 | -0.45 | 1.39  | 1.46               | 0.16           | 13.86          |
|               | SD    | 1.92  | 2.10  | 0.47  | 0.84               | 0.15           | 9.21           |
| Stage 4       | Mean  | 22.47 | -9.32 | 8.72  | 4.32               | 0.52           | 33.14          |
|               | SD    | 4.91  | 5.18  | 2.83  | 1.91               | 0.14           | 10.67          |

Mean sensitivity (MS), mean deviation (MD), pattern standard deviation (PSD), local spatial variability (LSV) and the AMD Severity Index are shown.

doi:10.1371/journal.pone.0039944.t002
The coefficient of variation for each stimulus location was calculated. Frequency of defect maps were constructed from the PD probability maps, which were used in preference to the total deviation analysis as they were less variable and less likely to be affected by the possible presence of diffuse lenticular changes. Concentric sectors of the 10° field, based on the frequency of PD defects, were used to evaluate the unweighted MD and change in MD with stage. We then derived a new index, the AMD Severity Index, using a weighted scoring system based on the PD defects and their locations within the 10° field. The Severity Index was examined for change with stage of AMD.

### Results

Visual field data from 27 eyes of 27 patients and 22 eyes of 22 normal subjects, were included in the analysis. There were 7 eyes

| Table 3. Kruskal-Wallis test of significant variation in visual field measures with advancing stage of AMD. |
|---------------------------------------------------------------|
|                | MD     | PSD    | LSV    | No. PD Defects | Severity Index |
| SAP             | Chi-square | 19.630 | 18.605 | 17.597         | 21.032         | 23.038         |
| p               | <0.001  | <0.001 | <0.001 | <0.001         | <0.001         |
| SWAP            | Chi-square | 22.095 | 26.576 | 23.878         | 26.765         | 28.797         |
| p               | <0.001  | <0.001 | <0.001 | <0.001         | <0.001         |

doi:10.1371/journal.pone.0039944.t003

### Table 4. Post hoc analyses (Mann-Whitney U test with Bonferroni adjustment) to detect significant differences in visual field measures between AMD stages and normal.

| SAP MD         | Stage | Stage 2–3 | Stage 4 |
|----------------|-------|-----------|--------|
| MD             | 0–1   | 0.129     | <0.001 |
|                |       | 0.221     | Normal |
|                |       | 0.905     | <0.001 |
|                |       | <0.001    | Stage 0–1 |
|                |       | 0.003     | Stage 2–3 |
|                |       | 0.002     | Stage 2–3 |
|                |       | 0.004     | Stage 0–1 |
|                |       | 0.004     | Stage 0–1 |
|                |       | 0.002     | Stage 2–3 |
|                |       | 0.042     | <0.001 |
|                |       | 0.219     | <0.001 |
|                |       | 0.001     | Stage 0–1 |
|                |       | 0.004     | Stage 2–3 |
|                |       | 0.744     | <0.001 |
|                |       | 0.020     | Normal |
|                |       | 0.067     | <0.001 |
|                |       | 0.007     | Stage 0–1 |
|                |       | 0.313     | <0.001 |
|                |       | 0.008     | Normal |
|                |       | 0.032     | <0.001 |
|                |       | 0.009     | Stage 2–3 |
| SAP PSD        | Stage | Stage 2–3 | Stage 4 |
|                | 0–1   | 0.785     | <0.001 |
|                |       | 0.296     | Normal |
|                |       | 0.321     | <0.001 |
|                |       | <0.001    | Stage 0–1 |
|                |       | 0.002     | Stage 2–3 |
|                |       | 0.004     | Stage 2–3 |
|                |       | 0.384     | <0.001 |
|                |       | 0.039     | Normal |
|                |       | <0.001    | Stage 0–1 |
|                |       | 0.001     | Stage 2–3 |
|                |       | 0.004     | Stage 0–1 |
|                |       | 0.007     | Stage 2–3 |
| SWAP PSD       | Stage | Stage 2–3 | Stage 4 |
|                | 0–1   | 0.098     | <0.001 |
|                |       | 0.017     | Normal |
|                |       | 0.251     | <0.001 |
|                |       | <0.001    | Stage 0–1 |
|                |       | 0.006     | Stage 2–3 |
|                |       | 0.004     | Stage 0–1 |
|                |       | 0.004     | Stage 0–1 |
|                |       | 0.002     | Stage 2–3 |
|                |       | 0.042     | <0.001 |
|                |       | 0.219     | <0.001 |
|                |       | 0.001     | Stage 0–1 |
|                |       | 0.251     | <0.001 |
|                |       | 0.004     | Stage 2–3 |
| SWAP LSV       | Stage | Stage 2–3 | Stage 4 |
|                | 0–1   | 0.337     | <0.001 |
|                |       | <0.001    | <0.001 |
|                |       | 0.005     | <0.001 |
|                |       | 0.005     | Stage 0–1 |
|                |       | 0.007     | Stage 2–3 |
|                |       | 0.183     | <0.001 |
|                |       | 0.013     | Stage 2–3 |
| SWAP No. PD defects | Stage | Stage 2–3 | Stage 4 |
|                  | 0–1   | 0.074     | <0.001 |
|                  |       | 0.020     | Normal |
|                  |       | 0.067     | <0.001 |
|                  |       | 0.007     | Stage 0–1 |
|                  |       | 0.313     | <0.001 |
|                  |       | 0.008     | Normal |
|                  |       | 0.032     | <0.001 |
|                  |       | 0.009     | Stage 2–3 |
| SWAP Severity Index | Stage | Stage 2–3 | Stage 4 |
|                    | 0–1   | 0.183     | <0.001 |
|                    |       | 0.013     | Normal |
|                    |       | 0.032     | <0.001 |
|                    |       | 0.009     | Stage 2–3 |
|                    |       | 0.183     | <0.001 |
|                    |       | 0.013     | Stage 2–3 |
|                    |       | 0.032     | <0.001 |
|                    |       | 0.009     | Stage 2–3 |
|                    |       | 0.183     | <0.001 |
|                    |       | 0.013     | Stage 2–3 |
|                    |       | 0.032     | <0.001 |
|                    |       | 0.009     | Stage 2–3 |
|                    |       | 0.183     | <0.001 |
|                    |       | 0.013     | Stage 2–3 |
|                    |       | 0.032     | <0.001 |
|                    |       | 0.009     | Stage 2–3 |
|                    |       | 0.183     | <0.001 |
|                    |       | 0.013     | Stage 2–3 |
|                    |       | 0.032     | <0.001 |
|                    |       | 0.009     | Stage 2–3 |
|                    |       | 0.183     | <0.001 |
|                    |       | 0.013     | Stage 2–3 |
|                    |       | 0.032     | <0.001 |
|                    |       | 0.009     | Stage 2–3 |
|                    |       | 0.183     | <0.001 |
|                    |       | 0.013     | Stage 2–3 |
|                    |       | 0.032     | <0.001 |
|                    |       | 0.009     | Stage 2–3 |
|                    |       | 0.183     | <0.001 |
|                    |       | 0.013     | Stage 2–3 |
|                    |       | 0.032     | <0.001 |
|                    |       | 0.009     | Stage 2–3 |
|                    |       | 0.183     | <0.001 |
|                    |       | 0.013     | Stage 2–3 |
|                    |       | 0.032     | <0.001 |
|                    |       | 0.009     | Stage 2–3 |

Results show the p-values for the mean deviation (MD), pattern standard deviation (PSD), local spatial variability (LSV), number of pattern deviation (PD) defects and AMD Severity Index. Significant differences are in bold and have a conservative Bonferroni adjustment for multiple comparisons.
doi:10.1371/journal.pone.0039944.t004
SAP (Spearman's rho = 0.455, p = 0.001) and SWAP (rho = 0.768) had evident for the Severity Index.

In SAP, more significant differences from normal were observed in the MD, PSD, LSV, and number of PD defects across the entire field. In SWAP, the MD had the fewest significant differences from normal, and the number of PD defects on PD analysis for SAP and SWAP as a function of stage of disease.

Figure 2 shows the measures MD, PSD, LSV and number of PD defects for normal and AMD subjects. Patients at stages 2–3 and 4 showed a greater variability than those at 0–1 and normal subjects.

All measures varied significantly (Kruskal-Wallis test) with the stage of AMD for both SAP and SWAP (Table 3). A greater number of post hoc differences (Mann-Whitney U test with Bonferroni adjustment; Table 4) were noted between subject groups for SWAP than for SAP, for the PSD and the LSV. Post hoc analysis (Table 4) revealed significant differences between normal subjects and AMD patients at stages 2–3 and 4, in SAP and in SWAP.

Figure 4 shows the measures MD, PSD, LSV and number of PD defects for normal and AMD subjects. Patients at stages 2–3 and 4 showed a greater variability than those at 0–1 and normal subjects.

Figure 5 shows the measures MD, PSD, LSV and number of PD defects for normal and AMD subjects. Patients at stages 2–3 and 4 showed a greater variability than those at 0–1 and normal subjects.

All measures varied significantly (Kruskal-Wallis test) with the stage of AMD for both SAP and SWAP (Table 3). A greater number of post hoc differences (Mann-Whitney U test with Bonferroni adjustment; Table 4) were noted between subject groups for SWAP than for SAP, for the PSD and the LSV. Overall, SWAP detected more differences from normal than SAP. In SWAP, the MD had the fewest significant differences from normal. In SAP more significant differences from normal were evident for the Severity Index.

There were significant correlations between LSV and PSD for SAP (Spearman's rho = 0.455, p = 0.001) and SWAP (rho = 0.768, p<0.001).

Coefficient of Variation

As expected, the AMD group yielded lower MS and greater SDs than normal group for SAP and SWAP (Table 2). Variability was compared using the coefficient of variation statistic [26,27] (SD/mean, expressed as %), which represents a normalised measure of dispersion such that distributions which differ in the magnitude of their measurement scales may be compared.

SWAP consistently revealed greater coefficients of variation than SAP (Figure 3). The AMD patients had higher values than normal. At AMD stages 0–1, mean coefficients of variation were only slightly greater than normal (normals: SAP 5±3%; SWAP 16±2%; Stage 0–1: SAP 6±3%, SWAP 21±5%) but at stage 4 large values were exhibited (SAP 44±20%; SWAP 105±89%).

Frequency of Defect

The frequency of defect maps (Figure 4) represent the percentage of eyes at each stimulus location which have significant defects on PD analysis for SAP and SWAP as a function of stage of disease. Maps are displayed as a right eye.

doi:10.1371/journal.pone.0039944.g004

graduated at stage 0 and stage 4.

Change in visual field measures with stage

Compared to normal subjects mean sensitivity (MS) values were decreased and SDs were increased in the AMD patients (Table 2). Figure 2 shows the measures MD, PSD, LSV and number of PD defects for normal and AMD subjects. Patients at stages 2–3 and 4 showed a greater variability than those at 0–1 and normal subjects.

All measures varied significantly (Kruskal-Wallis test) with the stage of AMD for both SAP and SWAP (Table 3). A greater number of post hoc differences (Mann-Whitney U test with Bonferroni adjustment; Table 4) were noted between subject groups for SWAP than for SAP, for the PSD and the LSV. Overall, SWAP detected more differences from normal than SAP. In SWAP, the MD had the fewest significant differences from normal. In SAP more significant differences from normal were evident for the Severity Index.

There were significant correlations between LSV and PSD for SAP (Spearman's rho = 0.455, p = 0.001) and SWAP (rho = 0.768, p<0.001).

Coefficient of Variation

As expected, the AMD group yielded lower MS and greater SDs than normal group for SAP and SWAP (Table 2). Variability was compared using the coefficient of variation statistic [26,27] (SD/mean, expressed as %), which represents a normalised measure of dispersion such that distributions which differ in the magnitude of their measurement scales may be compared.

SWAP consistently revealed greater coefficients of variation than SAP (Figure 3). The AMD patients had higher values than normal. At AMD stages 0–1, mean coefficients of variation were only slightly greater than normal (normals: SAP 5±3%; SWAP 16±2%; Stage 0–1: SAP 6±3%, SWAP 21±5%) but at stage 4 large values were exhibited (SAP 44±20%; SWAP 105±89%).

Frequency of Defect

The frequency of defect maps (Figure 4) represent the percentage of eyes at each stimulus location which have significant defects on PD analysis for SAP and SWAP as a function of stage of disease. Maps are displayed as a right eye.

doi:10.1371/journal.pone.0039944.g004

graduated at stage 0, 6 at stage 1, 5 at stage 2, 2 at stage 3 and 7 at stage 4. Data from stages were combined by the following grouping: stages 0–1, stages 2–3 and stage 4.

**Change in visual field measures with stage**

Compared to normal subjects mean sensitivity (MS) values were decreased and SDs were increased in the AMD patients (Table 2). Figure 2 shows the measures MD, PSD, LSV and number of PD defects for normal and AMD subjects. Patients at stages 2–3 and 4 showed a greater variability than those at 0–1 and normal subjects.

All measures varied significantly (Kruskal-Wallis test) with the stage of AMD for both SAP and SWAP (Table 3). A greater number of post hoc differences (Mann-Whitney U test with Bonferroni adjustment; Table 4) were noted between subject groups for SWAP than for SAP, for the PSD and the LSV. Overall, SWAP detected more differences from normal than SAP. In SWAP, the MD had the fewest significant differences from normal. In SAP more significant differences from normal were evident for the Severity Index.

There were significant correlations between LSV and PSD for SAP (Spearman’s rho = 0.455, p = 0.001) and SWAP (rho = 0.768, p<0.001).

Coefficient of Variation

As expected, the AMD group yielded lower MS and greater SDs than normal group for SAP and SWAP (Table 2). Variability was compared using the coefficient of variation statistic [26,27] (SD/mean, expressed as %), which represents a normalised measure of dispersion such that distributions which differ in the magnitude of their measurement scales may be compared.
The severity of disease. The finding of reduced MS and greater variability in sensitivity in the AMD patient group compared to the normal group is consistent with previous studies [3,4,5,6,9].

We quantified the visual field loss as a function of stage of AMD and found that the changes in SWAP were more significant than those in SAP. SWAP had a greater capability in detecting differences between the AMD groups and differences from normal, than SAP. Previous studies of blue-on-yellow perimetry in AMD [5,6] did not compare results to SAP, however in patients with diabetes, sensitivity loss in the 10–2 visual field, due to structural change, was better detected by SWAP than SAP [23,35,36,37]. The SWS pathway is vulnerable to a variety of retinal disease implying that SWS pathway sensitivity loss occurs at multiple sites of damage [38]. Possible explanations include reduced redundancy due to the sparse SWS system [39] and/or the smaller response range of the SWS cone system [40].

A secondary aim was to examine the location of visual field loss within the 10° field. A central scotoma within 5° was demonstrated in late stage AMD, supportive of previous findings of reduced SWS in the central compared to the peripheral 10° field in AMD [5]. Others have indicated paracentral scotoma and preservation of central vision in AMD [41,42], or no difference between central and peripheral sensitivity in the 10° SWAP field [6]. Possible explanations for these varied results include differences in instrumentation, sample sizes, classification of AMD and analyses.

In fact, we found that the most vulnerable region to AMD related sensitivity loss was the central 1°, in which the change was −3.9 dB per stage in SAP and −4.9 dB in SWAP. Our results suggested a symmetrical defect, from which the Severity Index was derived, to classify visual field defects on a continuous scale. In SAP, the Severity Index detected the most differences between groups. Thus, it may be a useful method for monitoring longitudinal progression of the visual field in AMD. From our findings, a Severity Index >0.1 in SAP and >0.2 in SWAP appeared abnormal, however a larger study is required to investigate this.

All visual field measures varied significantly with increasing stage of disease, however there was some functional overlap...
between stages. We found that focal measures of SWAP visual field loss, such as the PSD and number of PD defects, demonstrated greater capability in detecting AMD subjects from normal. In a previous study [23], detection of focal loss by the number of PD defects in SWAP, had a stronger relationship with diabetic retinopathy than SAP.

Of the focal indices, LSV is less common but statistically less manipulated than PSD, as well as significantly correlated with PSD. LSV is less influenced by pre-receptoral absorption, i.e. macular pigment and lenticular changes, which limit the interpretation of SWAP. Although the effect of lenticular absorption was minimised by our exclusion criteria, mild absorption and macular pigment effects may have influenced the SWAP data. However, significant attenuation of SWAP thresholds by macular pigment was not evident from normal defect maps (Figure 4), nor in our normal database. Correcting for macular pigment, which has a high within-subject variability [43], would artificially increase perimetric sensitivities and alter normal prediction limits. Since the effects of pre-receptoral absorption on SWAP are symmetrical and diffuse, a statistical approach has been recommended to separate focal loss [43,44] and our results support the conclusion that focal loss is of greater importance in AMD.

A limitation of SWAP was that overall larger coefficients of variation were found than in SAP (Figure 3), similar to previous findings [26]. However, this finding was skewed by large values at stages 3 and 4, where greater variability would be expected in scotomatous locations. In fact, coefficients of variation at earlier stages were near normal for both perimetry types, indicating SWAP as a reliable method to examine early stage AMD patients with minimal lens opacities.

In our study SWAP analysis had a high correlation with visual acuity as a means of detecting AMD and this raises the question as to what extra value SWAP measurement adds in assessing patients with AMD. It is known that central perimetry in AMD gives information about the spatial extent and depth of central visual

Figure 6. Calculation of Severity Index and change in Severity Index with stage of AMD. Based on Pattern Deviation (PD) maps, visual field sectors were weighted whereby the greatest weight corresponded to the central sector (Spatial Location Weight). This was then multiplied by a depth defect score according to the PD probability value (Pattern Deviation Weight). Middle box: Example calculation: the sum was then divided by the maximum possible score to give the Severity Index ranging between 0 and 1, where 0 indicates no field loss and 1 indicates maximum defects across the entire field. Bottom box: Boxplots representing the change in Severity Index as a function of stage of severity of disease, for standard perimetry (SAP) and short-wavelength automated perimetry (SWAP). Boxplot limits represent the 15th, 25th, 50th, 75th and 85th percentiles.
doi:10.1371/journal.pone.0039944.g006
loss that visual acuity cannot measure [45], and with increasing possibilities of medical intervention available, this aspect of visual function measurement is likely to become important. In fact, visual acuity appeared to better differentiate between early stage AMD and normal, than perimetry. Therefore the value of SAP and SWAP analysis in AMD is in research, rather than as a diagnostic tool.

Limitations of the study were the small number of eyes at individual stages, which led to the grouping of stages and the cross-sectional design of the study. The difference in SAP and SWAP normative databases limits the analyses, however use of the HFA Statpac analysis is standard in clinical practice and provides greater accuracy than collection of new SAP normative data. A longitudinal study in a larger sample, following visual field progression over several years is warranted, in which the Severity Index could be used to measure field defects on a continuous scale. In a larger sample it would be possible to differentiate results between late stage patients with geographic atrophy and choroidal neovascularisation. Specific consideration in a progression study, would be necessary to account for worsening cataracts and potential involvement of fixation later in the disease, which may affect the interpretation of visual field results. Furthermore, visual field testing may be useful in assessing the effectiveness of novel treatments in either preserving or improving visual field loss in patients with AMD, enrolled in a clinical study under appropriate exclusion criteria. Due to the strict exclusion criteria of our study, our findings are limited to AMD subjects suitable to visual field testing, i.e. those who have foveal fixation and clear ocular media.

The results present evidence of a relationship between the SWAP visual field and severity of AMD, whereby sensitivity declined with advancing stage of AMD. SWAP had greater capability in detecting early AMD than SAP. The importance of early detection of functional change in AMD is clinically relevant to possible earlier intervention or lifestyle changes. Sensitivity loss in AMD was focal in nature and the central field became less uniform as stage increased. SWAP defects occurred at similar locations but were deeper and wider than corresponding SAP defects. Although not all patients are suitable for SWAP examinations, our findings support it as a useful tool in research studies of visual loss in AMD.

Acknowledgments
Presented in part at the 2009 annual meeting of the Association for Research in Vision and Ophthalmology, Florida, for which the College of Optometrists provided a travel grant to J Acton.

Thanks to Vivienne Greenstein for scientific advice, Miriam Conway for providing the SWAP 10–2 normative database and Richard Armstrong for statistical advice.

Author Contributions
Conceived and designed the experiments: JHA JMG RPC. Performed the experiments: JHA. Analyzed the data: JHA JMG RPC. Contributed reagents/materials/analysis tools: JHA JMG RPC. Wrote the paper: JHA JMG RPC.

References

1. Resnikoff S, Pascolini D, Yonka’ale D, Kocur I, Pararajasegaram R, et al. (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82: 944–951.
2. Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesene SB, et al. (2009) Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 127: 533–540.
3. Mulena E, Degli Angeli C, Blazarino MC, Valenti M, Segato T (1997) Macular function impairment in eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci 38: 469–477.
4. Mulena E, Segato T, Blazarino MC, Degli Angeli C (1994) Macular drusen and the sensitivity of the central visual field. Doc Ophthalmol 88: 179–185.
5. Remky A, Ehlers AE (2005) Blue on yellow perimetry with scanning laser ophthalmoscopy in patients with age related macular disease. Br J Ophthalmol 89: 464–469.
6. Remky A, Lichtenberg K, Ehlers AE, Arend O (2001) Short wavelength automated perimetry in age related maculopathy. Br J Ophthalmol 85: 1432–1436.
7. Tolentino MJ, Miller S, Gaudio AR, Sandberg MA (1994) Visual field deficits in early age-related macular degeneration. Vision Res 34: 409–413.
8. Aitchson DA, Lovie-Kitchin JE, Swann PG (1996) Investigation of central visual fields in patients with age-related macular changes. Optom Vis Sci 67: 179–183.
9. Cheng AS, Vingrys AJ (1993) Visual losses in early age-related maculopathy. Optom Vis Sci 70: 89–96.
10. Freemonson C, Nilsson UL, Nilsson SE (1995) Colour contrast sensitivity in patients with soft drusen, an early stage of ARM. Doc Ophthalmol 90: 377–386.
11. Feild B, Brown B, Lovie-Kitchin J, Swann P (2005) Monitoring retinal function in early age-related maculopathy: visual performance after 1 year. Eye (Lond) 19: 1169–1177.

Figure 7. Boxplots representing the change in visual acuity with stage of severity of disease. The change in visual acuity (logMAR) as a function of stage of severity of disease and post hoc analyses (Mann-Whitney U test with Bonferroni adjustment) to detect significant differences in visual acuities between AMD stages and normal are shown. Boxplot limits represent the 15th, 25th, 50th, 75th and 85th percentiles. Significant differences in the posthoc analyses are the p-values in bold and have a conservative Bonferroni adjustment for multiple comparisons.

doi:10.1371/journal.pone.0039944.g007
21. Eisner A, Fleming SA, Klein ML, Mauldin WM (1987) Sensitivities in Older Eyes with Good Acuity – Eyes Whose Fellow Eye Has Exudative AMD. Invest Ophthalmol Vis Sci 28: 1832–1837.

22. Haegerstrom-Portnoy G, Brown B (1989) 2-Color Increment Thresholds in Early Age-Related Maculopathy. Clin Vis Sci 4: 165–172.

23. Bengtsson B, Heijl A, Agardh E (2005) Visual fields correlate better than visual acuity to severity of diabetic retinopathy. Diabetologia 48: 2494–2500.

24. Johnson CA, Adams AJ, Casson EJ, Brandt JD (1993) Progression of early glaucomatous visual field loss as detected by blue-on-yellow and standard white-on-white automated perimetry. Arch Ophthalmol 111: 651–656.

25. Johnson CA, Adams AJ, Casson EJ, Brandt JD (1993) Blue-on-yellow perimetry can predict the development of glaucomatous visual field loss. Arch Ophthalmol 111: 645–650.

26. Wild JM, Cubbidge RP, Pacey IE, Robinson R (1998) Statistical aspects of the normal visual field in short-wavelength automated perimetry. Invest Ophthalmol Vis Sci 39: 54–63.

27. Cubbidge RP, Hosking SL, Embleton S (2002) Statistical modelling of the central 10-degree visual field in short-wavelength automated perimetry. Graefes Arch Clin Exp Ophthalmol 240: 650–657.

28. Bengtsson B, Hellgren KJ, Agardh E (2008) Test-retest variability for standard automated perimetry and short-wavelength automated perimetry in diabetic patients. Acta Ophthalmol 86: 170–176.

29. Chylack LT Jr, Wolfe JK, Singer DM, Leske MC, Bullimore MA, et al. (1993) The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 111: 831–836.

30. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, et al. (1995) An international classification and grading system for age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39: 367–374.

31. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT (2003) The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol 121: 519–526.

32. Durand AC, Gould GM (1910) A method of determining ocular dominance. Journal of the American Medical Association 55: 369–370.

33. Crabb DP, Edgar DF, Firke FW, McNaught AL, Wynn HP (1995) New approach to estimating variability in visual field data using an image processing technique. Br J Ophthalmol 79: 213–217.

34. Conway M, Cubbidge RP, Hosking SL (2009) Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 49: 116.

35. Hudson C, Flanagan JG, Turner GS, Chen HC, Young LB, et al. (1998) Short-wavelength sensitive visual field loss in patients with clinically significant diabetic macular oedema. Diabetologia 41: 918–928.

36. Remky A, Arend O, Hendricks S (2000) Short-wavelength automated perimetry and capillary density in early diabetic maculopathy. Invest Ophthalmol Vis Sci 41: 274–281.

37. Agardh E, Stjernquist H, Heijl A, Bengtsson B (2006) Visual acuity and perimetry as measures of visual function in diabetic macular oedema. Diabetologia 49: 200–206.

38. Greenstein VC, Hood DC, Ritch R, Steinberger D, Carr RE (1989) S (blue) cone pathway vulnerability in retinitis pigmentosa, diabetes and glaucoma. Invest Ophthalmol Vis Sci 30: 1722–1737.

39. Johnson CA (1994) Selective versus nonselective losses in glaucoma. J Glaucoma 3 Suppl 1: S32–44.

40. Hood DC, Benimoff NI, Greenstein VC (1984) The Response Range of the Blue-Cone Pathways – A Source of Vulnerability to Disease. Invest Ophthalmol Vis Sci 25: 864–867.

41. Hart WM, Burde RM (1983) 3-Dimensional Topography of the Central Visual-Field – Sparring of Foveal Sensitivity in Macular Disease. Ophthalmology 90: 1028–1030.

42. Swann PG, Lovie-Kocher JE (1991) Age-Related Maculopathy.2: The Nature of the Central Visual-Field Loss. Ophthalmolog Physiol Opt 11: 59–70.

43. Wild JM, Hudson C (1995) The Attenuation of Blue-On-Yellow Perimetry by the Macular Pigment. Ophthalmology 102: 911–917.

44. Sample PA, Martinez GA, Weinreb RN (1994) Short-Wavelength Automated Perimetry Without Lens Density Testing. Am J Ophthalmol 118: 632–641.

45. Anderson AJ, Johnson CA, Werner JS (2011) Measuring Visual Function in Age-Related Macular Degeneration with Frequency-Doubling (Matrix) Perimetry. Optom Vis Sci 88: 806–815.